Patents by Inventor Jolie Anne Bastian

Jolie Anne Bastian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110190304
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 4, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Philip Arthur Hipskind, Daniel Jon Sall, Takako Wilson (nee Takakuwa)
  • TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110178093
    Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: November 9, 2009
    Publication date: July 21, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
  • Kinase inhibitors
    Patent number: 7652015
    Abstract: The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: January 26, 2010
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jesus Andres Blas de Blas, Alfonso De Dios, Kevin John Hudziak, Tiechao Li, Beatriz López De Uralde-Garmendia, Mary Margaret Mader, Michael Ray Myers, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Kinase Inhibitors
    Publication number: 20080269244
    Abstract: The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 25, 2006
    Publication date: October 30, 2008
    Inventors: Jolie Anne Bastian, Jesus Andres Blas de Blas, Alfonso De Dios, Kevin John Hudziak, Tiechao Li, Beatriz Lopez De Uralde-Garmendia, Mary Margaret Mader, Michael Ray Myers, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders
    Patent number: 7297706
    Abstract: Compounds of formula (I) in which R, R1, R2, n and X1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: July 11, 2006
    Date of Patent: November 20, 2007
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Wiley, Daniel Jon Sall, Christopher William Murray, Stephen Clinton Young, Jolie Anne Bastian
  • ?adrenergic agonists
    Patent number: 7265127
    Abstract: The present invention relates to 2-imidazo[1,2-a]pyridine group containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: September 4, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • ?adrenergic agonists
    Patent number: 7253181
    Abstract: The present invention relates to pyrrolopyridine-3-yl group containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: August 7, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • ?adrenergic agonists
    Patent number: 7241772
    Abstract: The present invention relates to 2-imidazo[1,5-a]pyridine containing ?3 adrenergic receptor agonists or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: July 10, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • ?3 adrenergic agonists
    Patent number: 7208505
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: April 24, 2007
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Rushad Eruch Karanjawala, Cynthia Darshini Jesudason, Theo Schotten, Britta Evers, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • 3-Substituted oxindole ?3 agonists
    Patent number: 7205407
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • 3-substituted oxindole ?3 agonists
    Patent number: 7087635
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz, Theo Schotten, Gerd Reuhter
  • Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders
    Patent number: 7078415
    Abstract: Compounds of formula (I) in which R, R1, R2, n and X1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: July 18, 2006
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Wiley, Daniel Jon Sall, Christopher William Murray, Stephen Clinton Young, Jolie Anne Bastian
  • ?Adrenergic agonists
    Patent number: 7071208
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: July 4, 2006
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Gerd Ruehter, Daniel Jon Sall, Theo Schotten
  • 3-substituted oxindole ?-3 agonists
    Patent number: 6911463
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: June 28, 2005
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders
    Publication number: 20040249155
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 1, 2004
    Publication date: December 9, 2004
    Inventors: Michael Robert Wiley, Daniel Jon Sall, Christopher William Murray, Stephen Clinton Young, Jolie Anne Bastian
  • 3-substituted oxindole beta-3 agonists
    Publication number: 20040242668
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Application
    Filed: February 11, 2004
    Publication date: December 2, 2004
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Substituted tricyclics
    Patent number: 6713645
    Abstract: A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Susan Elizabeth Draheim, Robert Delane Dillard, Edward David Mihelich, Jason Scott Sawyer, Douglas Wade Beight, Michael LeRoy Phillips, Tulio Suarez, Daniel Jon Sall, Jolie Anne Bastian, Michael Lyle Denney, Gary Alan Hite, Michael Dean Kinnick, Robert Theodore Vasileff, John Michael Morin, Jr., Ho-Shen Lin, Michael Enrico Richett, Richard Waltz Harper, John McNeill McGill, III, Benjamin Alan Anderson, Nancy Kay Harn, Richard James Loncharich, Richard Walter Schevitz
  • Antithrombotic agents
    Patent number: 6620837
    Abstract: This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of defined compounds of formula (I) as thrombin inhibitors.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: September 16, 2003
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, John Eldon Toth, Kumiko Takeuchi, Todd Johnathan Kohn, Jolie Anne Bastian
  • Antithrombotic agents
    Patent number: 6265416
    Abstract: This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: July 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Matthew Joseph Fisher, Richard Waltz Harper, Ho-Shen Lin, Jefferson Ray McCowan, Daniel Jon Sall, Gerald Floyd Smith, Kumiko Takeuchi, Michael Robert Wiley, Minsheng Zhang
  • Antithrombotic diamines
    Patent number: 6251921
    Abstract: This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: June 26, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Nickolay Yuri Chirgadze, Michael Lyle Denney, Matthew Joseph Fisher, Robert James Foglesong, Richard Waltz Harper, Mary George Johnson, Valentine Joseph Klimkowski, Todd Jonathan Kohn, Ho-Shen Lin, Michael Patrick Lynch, Jefferson Ray McCowan, Alan David Palkowitz, Michael Enrico Richett, Daniel Jon Sall, Gerald Floyd Smith, Kumiko Takeuchi, Jennifer Marie Tinsley, Minsheng Zhang